cvot tirzepatide SURPASS-CVOT Shows Mounjaro Surpasses Trulicity in CV Outcomes π« EASD 2025: Tirzepatide (SURPASS-CVOT)
Description
About this article Cite this article Niu, M., Guo, J., Yang, Y
On April 30, 2026 , the FDA proposed leaving semaglutide, tirzepatide, and liraglutide off the 503B bulks list entirely, saying there is no clinical need for large-scale compounding
Compounded semaglutide costs 6075% less than branded Wegovy because it bypasses brand-name patent premiums, pre-filled pen device costs, and insurance billing overhead
an increase in score indicating worsening as the disease progresses 6,7
The compounded versions offered by both TelosRX and Clover Meds are not FDA-approved
S., Sharma A
